Innoviva Specialty Therapeutics 宣布，已与 Dr. Reddy's Laboratories Ltd. 就抗菌药物 Xacduro®（sulbactam-durlobactam）在特定国际市场达成一项分销及授权协议。
根据协议条款，Dr. Reddy's 将获得在协议涵盖区域内商业化 Xacduro® 的独家权利。该合作旨在加速这一重要治疗药物在全球更多地区的可及性，以应对由鲍曼不动杆菌-醋酸钙复合体引起的医院获得性细菌性肺炎和呼吸机相关细菌性肺炎。
此次合作标志着 Innoviva 旗下专业治疗部门在拓展其产品全球影响力方面迈出了关键一步。Xacduro® 此前已获得美国食品药品监督管理局（FDA）批准，此次与国际知名制药公司 Dr. Reddy's 的合作，有望进一步优化其在选定国际市场的分销网络和商业化进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.